Long-term outcomes of LDR-brachytherapy for localized prostate cancer.

IF 3.5 3区医学 Q2 ONCOLOGY

Frontiers in Oncology Pub Date : 2025-01-16 eCollection Date: 2024-01-01 DOI:10.3389/fonc.2024.1326355

Lauri Mäkelä, Anssi Pétas, Arto Mikkola, Harri Visapää

{"title":"Long-term outcomes of LDR-brachytherapy for localized prostate cancer.","authors":"Lauri Mäkelä, Anssi Pétas, Arto Mikkola, Harri Visapää","doi":"10.3389/fonc.2024.1326355","DOIUrl":null,"url":null,"abstract":"Introduction: This retrospective study aims to evaluate the long-term efficacy and urinary toxicity of LDR-brachytherapy for localized prostate cancer.Materials and methods: 235 primary prostate cancer patients treated with LDR-brachytherapy and subsequently followed up in our center were included in this study. Biochemical relapse free survival (bRFS), overall survival (OS), and cancer-specific survival (CSS) were evaluated. Additionally, the incidence of late urinary complications was recorded.Results: Median follow-up time was 11,6 years. 181 patients (77%) were classified as low-risk patients, while 52 patients (22,1%) were intermediate risk. The overall bRFS was 83,8% at 5 years and 72,4% at 10 years. 5- and 10-year OS were 97,8% and 87,8% respectively. There was no statistically significant difference in bRFS or OS between different risk groups. The rate of late urinary complications was 8,9%. Volume of prostate had a statistically significant effect on bRFS, as smaller prostate volumes led to worse bRFS.Conclusions: This retrospective study shows that LDR brachytherapy is an effective treatment for low- and intermediate risk prostate cancer patients with relatively low but still significant risk of late urinary complications.","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1326355"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11779706/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2024.1326355","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This retrospective study aims to evaluate the long-term efficacy and urinary toxicity of LDR-brachytherapy for localized prostate cancer.

Materials and methods: 235 primary prostate cancer patients treated with LDR-brachytherapy and subsequently followed up in our center were included in this study. Biochemical relapse free survival (bRFS), overall survival (OS), and cancer-specific survival (CSS) were evaluated. Additionally, the incidence of late urinary complications was recorded.

Results: Median follow-up time was 11,6 years. 181 patients (77%) were classified as low-risk patients, while 52 patients (22,1%) were intermediate risk. The overall bRFS was 83,8% at 5 years and 72,4% at 10 years. 5- and 10-year OS were 97,8% and 87,8% respectively. There was no statistically significant difference in bRFS or OS between different risk groups. The rate of late urinary complications was 8,9%. Volume of prostate had a statistically significant effect on bRFS, as smaller prostate volumes led to worse bRFS.

Conclusions: This retrospective study shows that LDR brachytherapy is an effective treatment for low- and intermediate risk prostate cancer patients with relatively low but still significant risk of late urinary complications.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.